Skip to main content

Table 1 Characteristics of the studies involved

From: Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials

Research Sample Age/years Sex ratio (males/females) Course of T2DM/years Interventions Duration Outcomes
T/C T C T C T C T C   
Zha 2018 [16] 30/30 – – – – – – LIR(0.6 to 1.8 mg qd ih) plus Huang kui capsule Huangkui Capsules 2.5 g tid po 2 months ACDF
Cao 2020 [17] 30/30 55.21 ± 6.32 56.12 ± 6.92 17/13 15/15 4.08 ± 1.74 4.19 ± 1.52 LIR(0.6 to 1.2 mg qd po) plus nephritis rehabilitation tablets nephritis rehabilitation tablets 0.48 g/tablet, 5tablets/time, tid 12 weeks ABCGHIJK
Dong 2018 [18] 43/43 53.7 ± 6.2 54.6 ± 8.7 20/23 23/20 – – LIR(0.6 to 1.8 mg qd ih) + INS INS 6 months ABCDEFGH
Chen 2016 [19] 30/31 – – – – – – LIR(0.6 to 1.8 mg qd ih) + RT RT 24 weeks ACDEH
Hu Yanyun 2018 [20] 55/55 59.64 ± 6.51 59.66 ± 6.54 35/20 37/18 6.28 ± 1.23 6.39 ± 1.14 LIR(0.6 to 1.2 mg qd ih)plus RT RT 8 weeks ABCHK
Ren Lijuan 2019 [21] 15/15 44.8 ± 2.7 51.3 ± 2.9 7/8 9/6 – – LIR (0.6 to 1.8 mg tid po) plus huangkui capsules Huangkui Capsules 2.5 g tid 6 months ABCF
Ren Wei 2015 [22] 24/24 – – – – – – LIR(0.6 to 1.8 mg qd ih) + RT RT 6 months ACDFH
Shi 2019 [23] 30/30 57.32 ± 3.69 57.63 ± 3.12 17/13 18/12 7.13 ± 2.24 7.08 ± 1.71 LIR (0.6 to 1.2 mg qd ih) plus Benazepril 10 mg qd Benazepril 10 mg qd 10 weeks CHJKH
Yang 2016 [24] 100/100 66.8 ± 14.7 67.4 ± 13.5 45/55 48/52 – – LIR (0.6 to 1.2 mg qd ih) plus Telmisartan 40 mg qd Telmisartan 40 mg qd 10 weeks CHJK
Zhao 2014 [25] 19/26 – – – – – – LIR (0.6 to 1.8 mg qd ih) plus Valsartan Valsartan 80 mg qd 6 months CDI
Zheng 2015 [26] 110/110 58 ± 4.9 57 ± 5.1 67/43 65/45 6.9 ± 2.8 7.1 ± 2.4 LIR (0.6 to 1.2 mg qd ih) plus INS INS 4 weeks ADGH
Hu Linlin 2018 [27] 30/30 42.5 ± 11.6 41.3 ± 10.7 18/12 17/13 – – LIR(0.6 to 1.8 mg tid po) plus huangkui capsules Huangkui Capsules 2.5 g tid po 6 months ACDF
Aiyitan 2017 [28] 89/73 58.1 ± 8.1 57.8 ± 7.9 49/40 39/34 – – LIR(0.6 to 1.8 mg qd ih) plus RT RT 8 weeks ABF
Shen 2017 [29] 30/30 – – 17/13 16/14 – – LIR (0.6 to 1.2 mg qd ih) pluse Olmesartan 20 mg/d Olmesartan 20 mg/d 6 months ACFHJK
Liu Rui 2016 [30] 59/75 57.5 ± 7.4 58.2 ± 7.9 33/26 43/32 – – LIR (0.6 to 1.2 mg qd ih) plus RT RT 8 weeks ABF
Liu Chuyv 2015 [31] 13/13 – – – – – – LIR (0.6 to 1.2 mg qd ih) + Olmesartan Olmesartan 20 mg qd + INS 6 months DFI
Li 2017 [32] 21/21 48.2 ± 9.0 49.1 ± 8.3 11/10 13/8 4.2 ± 1.1 7.38 ± 1.5 LIR plus RT RT + INS 12 weeks ABCDEGH
Jian 2018 [33] 58/58 56.51 ± 6.05 56.33 ± 8.63 32/26 29/29 – – LIR (0.6 mg to 1.2 mg qd ih) plus Metformin Metformin 1 g bid 3 months ABCDFHJK
  1. LIR liraglutide, RT routine treatment, INS insulin
  2. A. FBG
  3. B. PBG
  4. C. HbA1c
  5. D. BMI
  6. E. eGFR
  7. F. UACR
  8. G. BUN
  9. H. Scr
  10. I. Cysc
  11. J. IL-6
  12. K. TNF-α
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us